Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis

BMC Medical Genetics

Volumn 12, Issue , 2011, Pages

  Somkrua, Ratchadaporn ^a   Eickman, Elizabeth E ^b   Saokaew, Surasak ^c   Lohitnavy, Manupat ^a   Chaiyakunapruk, Nathorn ^a,d,e  

^a NARESUAN UNIVERSITY   (Thailand)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PHAYAO   (Thailand)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Allopurinol; Human Leukocyte Antigen; Meta Analysis; Severe Cutaneous Reaction; Stevens Johnson Syndrome; Toxic Epidermal Necrolysis

Indexed keywords

ALLOPURINOL; HLA B ANTIGEN; HLA B*58:01 ANTIGEN; HLA-B*58:01 ANTIGEN;

ALLELE; ARTICLE; ASIAN; CINAHL; COCHRANE LIBRARY; EMBASE; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MEDLINE; POPULATION GENETICS; PSYCINFO; STATISTICAL ANALYSIS; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; WORLD HEALTH ORGANIZATION; ADULT; AGED; CASE CONTROL STUDY; FEMALE; GENETICS; GENOTYPE; HETEROZYGOTE; MALE; META ANALYSIS; MIDDLE AGED; REVIEW; RISK;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ALLOPURINOL; CASE-CONTROL STUDIES; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; GENOTYPE; HETEROZYGOTE; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; STEVENS-JOHNSON SYNDROME;

EID: 80052596861     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-12-118     Document Type: Article

References (47)

1. Chan H, Stern R, Arndt K, Langlois J, Jick S, Jick H, Walker A. The incidence of erythema multiforme, sevens-johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990, 126(1):43-47. 10.1001/archderm.126.1.43, 2404462.
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331(19):1272-1285. 10.1056/NEJM199411103311906, 7794310.
3. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996, 49(7):769-773. 10.1016/0895-4356(96)00035-2, 8691227.
4. Mockenhaupt M, Norgauer J. Cutaneous adverse drug reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergy Clin Immunol Int 2002, 14:143-150.
5. Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review. Crit Care Med 2011, 39(6):1521-1532. 10.1097/CCM.0b013e31821201ed, 21358399.
6. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005, 209(2):123-129. 10.1016/j.tox.2004.12.022, 15767024.
7. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008, 128(1):35-44. 10.1038/sj.jid.5701033, 17805350.
8. Melsom R. Familial hypersensitivity to allopurinol with subsequent desensitization. Rheumatology (Oxford) 1999, 38(12):1301.
9. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007, 7:317-323. 10.1097/ACI.0b013e3282370c5f, 17620823.
10. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005, 102(11):4134-4139. 10.1073/pnas.0409500102, 554812, 15743917.
11. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008, 9(11):1617-1622. 10.2217/14622416.9.11.1617, 19018717.
12. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008, 18(2):99-107. 10.1097/FPC.0b013e3282f3ef9c, 18192896.
13. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009, 19(9):704-709. 10.1097/FPC.0b013e328330a3b8, 19696695.
14. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, Park HW, Chang YS, Jang IJ, Cho SH, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011, 21(5):303-307. 10.1097/FPC.0b013e32834282b8, 21301380.
15. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, Park HW, Chang YS, Cho SH, Min KU, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011, 0:1-6.
16. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994, 102(6):28S-30S. 10.1111/1523-1747.ep12388434, 8006430.
17. Bastuji-Garin S, Rzany B, Stern R. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erytherma multiforme. Arch Dermatol 1993, 129(1):92-96. 10.1001/archderm.129.1.92, 8420497.
18. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006, 55(1):9-16. 10.2332/allergolint.55.9, 17075281.
19. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (Accessed June 1, 2011)., http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
20. Tanaka H, Akaza T, Juji T. Report of the Japanese Central Bone Marrow Data Center. Clin Transpl 1996, 139-144.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188. 10.1016/0197-2456(86)90046-2, 3802833.
22. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):1539-1558. 10.1002/sim.1186, 12111919.
23. Begg C, Berlin J. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989, 81(2):107-115. 10.1093/jnci/81.2.107, 2642556.
24. Egger M, Smith G. Bias in location and selection of studies. BMJ 1998, 316(7124):61-66. 2665334, 9451274.
25. Hanioka T, Ojima M, Tanaka K, Matsuo K, Sato F, Tanaka H. Causal assessment of smoking and tooth loss: A systematic review of observational studies. BMC Public Health 2011, 11(1):221. 10.1186/1471-2458-11-221, 3087682, 21477320.
26. Loke Y, Price D, Herxheimer A, . the Cochrane Adverse Effects Methods G Systematic reviews of adverse effects: framework for a structured approach. BMC Medical Research Methodology 2007, 7(1):32. 10.1186/1471-2288-7-32, 1933432, 17615054, the Cochrane Adverse Effects Methods G.
27. Smith L, Foxcroft D. The effect of alcohol advertising, marketing and portrayal on drinking behaviour in young people: systematic review of prospective cohort studies. BMC Public Health 2009, 9(1):51. 10.1186/1471-2458-9-51, 2653035, 19200352.
28. Wahabi H, Alzeidan R, Bawazeer G, Alansari L, Esmaeil S. Preconception care for diabetic women for improving maternal and fetal outcomes: a systematic review and meta-analysis. BMC Pregnancy and Childbirth 2010, 10(1):63. 10.1186/1471-2393-10-63, 2972233, 20946676.
29. Munafo MR, Flint J. Meta-analysis of genetic association studies. Trends Genet 2004, 20(9):439-444. 10.1016/j.tig.2004.06.014, 15313553.
30. Klein J, Sato A. The HLA system, first of two parts. N Engl J Med 2000, 343(10):702-709. 10.1056/NEJM200009073431006, 10974135.
31. Halevy S, Mockenhaupt M, Fagot JP, Bavinck JNB, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008, 58:25-32. 10.1016/j.jaad.2007.08.036, 17919772.
32. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993, 27(3):337-343.
33. Markel A. Allopurinol-induced DRESS syndrome. Isr Med Assoc J 2005, 7:656-660.
34. Bugelski PJ. Genetic aspects of immune-mediated adverse drug effects. Nat Rev Drug Discov 2005, 4:59-69. 10.1038/nrd1605, 15688073.
35. Stevanovic S. Structural basis of immunogenicity. Transpl Immunol 2002, 10:133-136. 10.1016/S0966-3274(02)00059-X, 12216943.
36. Ou YC, Conolly RB, Thomas RS, Gustafson DL, Long ME, Dobrev ID, Chubb LS, Xu Y, Lapidot SA, Andersen ME, et al. Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay. Toxicol Sci 2003, 73(2):301-314. 10.1093/toxsci/kfg078, 12700395.
37. Conolly RB, Andersen ME. Hepatic foci in rats after diethylnitrosamine initiation and 2,3,7,8-tetrachlorodibenzo-p-dioxin promotion: evaluation of a quantitative two-cell model and of CYP 1A1/1A2 as a dosimeter. Toxicol Appl Pharmacol 1997, 146(2):281-293. 10.1006/taap.1997.8248, 9344896.
38. Lu Y, Lohitnavy M, Reddy M, Lohitnavy O, Eickman E, Ashley A, Gerjevic L, Xu Y, Conolly RB, Yang RS. Quantitative analysis of liver GST-P foci promoted by a chemical mixture of hexachlorobenzene and PCB 126: implication of size-dependent cellular growth kinetics. Arch Toxicol 2008, 82(2):103-116. 10.1007/s00204-007-0238-x, 17874069.
39. Ou YC, Conolly RB, Thomas RS, Xu Y, Andersen ME, Chubb LS, Pitot HC, Yang RS. A clonal growth model: time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay. Cancer Res 2001, 61(5):1879-1889.
40. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3(5):541-547. 10.1016/1074-7613(95)90125-6, 7584144.
41. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270(5238):985-988. 10.1126/science.270.5238.985, 7481803.
42. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006, 7(6):813-818. 10.2217/14622416.7.6.813, 16981842.
43. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, Hu SL, Wu MT, Chen GS, Wong TW, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006, 16(4):297-306. 10.1097/01.fpc.0000199500.46842.4a, 16538176.
44. Ikeda H, Takahashi Y, Yamazaki E, Fujiwara T, Kaniwa N, Saito Y, Aihara M, Kashiwagi M, Muramatsu M. HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions. Epilepsia 2010, 51(2):297-300. 10.1111/j.1528-1167.2009.02269.x, 19694795.
45. Middleton D, Menchaca L, Rood H, Komerofsky R. New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens 2003, 61(5):403-407. 10.1034/j.1399-0039.2003.00062.x, 12753660.
46. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, et al. HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 2010, 51(12):2461-2465. 10.1111/j.1528-1167.2010.02766.x, 21204807.
47. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011, 127(3 Suppl):S60-66.